Logo image of IVA

INVENTIVA SA - ADR (IVA) Stock Overview

NASDAQ:IVA - US46124U1079 - ADR

4.475 USD
+0.21 (+5.05%)
Last: 8/22/2025, 8:17:04 PM

IVA Key Statistics, Chart & Performance

Key Statistics
52 Week High4.7
52 Week Low1.53
Market Cap622.40M
Shares139.08M
Float115.90M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-1.66
PEN/A
Fwd PEN/A
Earnings (Next)09-25 2025-09-25
IPO02-15 2017-02-15
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


IVA short term performance overview.The bars show the price performance of IVA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 10 20 30 40 50

IVA long term performance overview.The bars show the price performance of IVA in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 40 60 80

The current stock price of IVA is 4.475 USD. In the past month the price increased by 41.32%. In the past year, price increased by 86.46%.

INVENTIVA SA - ADR / IVA Daily stock chart

IVA Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.89 372.04B
AMGN AMGEN INC 13.47 158.13B
GILD GILEAD SCIENCES INC 14.83 142.41B
VRTX VERTEX PHARMACEUTICALS INC 23.32 101.30B
REGN REGENERON PHARMACEUTICALS 12.92 62.48B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 59.56B
ARGX ARGENX SE - ADR 71.2 40.39B
ONC BEONE MEDICINES LTD-ADR 6.35 37.29B
INSM INSMED INC N/A 27.88B
BNTX BIONTECH SE-ADR N/A 26.66B
NTRA NATERA INC N/A 22.73B
BIIB BIOGEN INC 8.7 20.42B

About IVA

Company Profile

IVA logo image Inventiva SA is a clinical-stage biopharmaceutical company, which focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH, and other diseases with significant unmet medical need. The company is headquartered in Daix, Occitanie and currently employs 109 full-time employees. The company went IPO on 2017-02-15. The firm focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.

Company Info

INVENTIVA SA - ADR

50 rue de Dijon, Daix

Daix OCCITANIE 21121 FR

CEO: Frederic Cren

Employees: 116

IVA Company Website

IVA Investor Relations

Phone: 33380447500

INVENTIVA SA - ADR / IVA FAQ

What is the stock price of INVENTIVA SA - ADR today?

The current stock price of IVA is 4.475 USD. The price increased by 5.05% in the last trading session.


What is the ticker symbol for INVENTIVA SA - ADR stock?

The exchange symbol of INVENTIVA SA - ADR is IVA and it is listed on the Nasdaq exchange.


On which exchange is IVA stock listed?

IVA stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for INVENTIVA SA - ADR stock?

12 analysts have analysed IVA and the average price target is 9.53 USD. This implies a price increase of 112.97% is expected in the next year compared to the current price of 4.475. Check the INVENTIVA SA - ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is INVENTIVA SA - ADR worth?

INVENTIVA SA - ADR (IVA) has a market capitalization of 622.40M USD. This makes IVA a Small Cap stock.


How many employees does INVENTIVA SA - ADR have?

INVENTIVA SA - ADR (IVA) currently has 116 employees.


What are the support and resistance levels for INVENTIVA SA - ADR (IVA) stock?

INVENTIVA SA - ADR (IVA) has a support level at 4.25. Check the full technical report for a detailed analysis of IVA support and resistance levels.


Is INVENTIVA SA - ADR (IVA) expected to grow?

The Revenue of INVENTIVA SA - ADR (IVA) is expected to grow by 266.89% in the next year. Check the estimates tab for more information on the IVA EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy INVENTIVA SA - ADR (IVA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does INVENTIVA SA - ADR (IVA) stock pay dividends?

IVA does not pay a dividend.


When does INVENTIVA SA - ADR (IVA) report earnings?

INVENTIVA SA - ADR (IVA) will report earnings on 2025-09-25.


What is the Price/Earnings (PE) ratio of INVENTIVA SA - ADR (IVA)?

INVENTIVA SA - ADR (IVA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.66).


What is the Short Interest ratio of INVENTIVA SA - ADR (IVA) stock?

The outstanding short interest for INVENTIVA SA - ADR (IVA) is 0.01% of its float. Check the ownership tab for more information on the IVA short interest.


IVA Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to IVA. When comparing the yearly performance of all stocks, IVA is one of the better performing stocks in the market, outperforming 94.49% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

IVA Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to IVA. IVA may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

IVA Financial Highlights

Over the last trailing twelve months IVA reported a non-GAAP Earnings per Share(EPS) of -1.66. The EPS decreased by -20.47% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -154.84%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%-76.47%
Sales Q2Q%-41.21%
EPS 1Y (TTM)-20.47%
Revenue 1Y (TTM)-47.37%

IVA Forecast & Estimates

12 analysts have analysed IVA and the average price target is 9.53 USD. This implies a price increase of 112.97% is expected in the next year compared to the current price of 4.475.

For the next year, analysts expect an EPS growth of 63.99% and a revenue growth 266.89% for IVA


Analysts
Analysts86.67
Price Target9.53 (112.96%)
EPS Next Y63.99%
Revenue Next Year266.89%

IVA Ownership

Ownership
Inst Owners54.98%
Ins Owners6.82%
Short Float %0.01%
Short Ratio0.44